Tag: ranger
Boston Scientific announces position on FDA update about use of paclitaxel-coated...
Following yesterday's news that the US Food and Drug Administration (FDA) has changed its stance on the use of paclitaxel-coated devices to treat peripheral...
Two-year Ranger DCB data demonstrate “sustained, high rate” of device efficacy
Patients treated with the Ranger drug-coated balloon (DCB; Boston Scientific) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year...
Trialists’ insights on the 2-year results from the COMPARE trial
NOTE: This video is ONLY available to watch in selected countries and geographies
Sabine Steiner (Leipzig, Germany) sits down with Michael Jaff, the CMO...
COMPARE trial shows low dose DCB is “as safe and efficacious”...
Sabine Steiner (Leipzig, Germany) talks to Vascular News about the 24-month results from the COMPARE trial – which were presented at LINC 2021 (The...
LINC 2021: Head-to-head trials take centre stage in drug-eluting technology late-breaking...
Data from two head-to-head trials on drug-eluting technologies in femoral artery treatment were presented during a late-breaking session at LINC 2021 (The Leipzig Interventional...
Boston Scientific receives FDA approval for the Ranger DCB
Boston Scientific announced it has received US Food and Drug Administration (FDA) approval of the Ranger drug-coated balloon (DCB), developed for the treatment of...
COMPARE RCT shows similar key outcomes between low- and high-dose drug-coated...
The first head-to-head randomised controlled trial to directly compare two different drug-coated balloons—the lower-dose density (2μg/mm2) Ranger and higher-dose density (3.5μg/mm2) IN.PACT—showed similar results...
LINC 2020: High- and low-dose paclitaxel-coated balloons exhibit comparable results at...
At the 2020 Leipzig Interventional Course (28–31 January, Leipzig, Germany), Sabine Steiner (University of Leipzig, Leipzig, Germany) presented one-year results of the COMPARE-RTC of...
First data from head-to-head comparison of Ranger and IN.PACT drug-coated balloons...
Early data from the first randomised controlled trial to compare two drug-coated balloons (DCBs) suggest that the primary patency obtained with the Ranger DCB...
Positive results for Boston Scientific Ranger paclitaxel-coated PTA balloon catheter
Positive results from the RANGER SFA trial for Boston Scientific’s Ranger paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter have been presented at the 2017...
